Infect Chemother.  2022 Dec;54(4):610-620. 10.3947/ic.2022.0162.

Clinical Utility of Procalcitonin on Antibiotic Stewardship: A Narrative Review

• Kim JH

• KMID: 2537702
• DOI: http://doi.org/10.3947/ic.2022.0162

Abstract

Procalcitonin (PCT) was discovered as a useful marker for bacterial infection. Following its discovery, there have been a substantial number of clinical studies conducted to evaluate the presence of bacterial infections, and to guide antibiotic treatment by the stratified levels of PCT. Clinical evidence suggests that antibiotic treatment by PCT-guided antibiotic stewardship has been associated with a reduction in antibiotic usage without an increase in adverse outcomes. The use of PCT was approved by the Food and Drug Administration in the United States of America in 2017 to guide antibiotic treatment in sepsis and lower respiratory tract infections (LRTIs). In Korea, the use of PCT for sepsis and for pneumonia was approved in 2015 and 2022, respectively. This review will discuss the clinical utility of PCT on antibiotic stewardship in the management of sepsis and LRTIs including pneumonia.

Keyword

Procalcitonin; Antimicrobial stewardship; Sepsis; Respiratory tract infection; Pneumonia